ReNeuron Group plc – LSE:RENE.L
ReNeuron Group stock price today
ReNeuron Group stock price monthly change
ReNeuron Group stock price quarterly change
ReNeuron Group stock price yearly change
ReNeuron Group key metrics
Market Cap | 1.92M |
Enterprise value | 260.49M |
P/E | -0.67 |
EV/Sales | 42.95 |
EV/EBITDA | -19.43 |
Price/Sales | 0.45 |
Price/Book | 0.38 |
PEG ratio | -0.04 |
EPS | -0.13 |
Revenue | 373.5K |
EBITDA | -8.86M |
Income | -7.60M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -188.16% |
Oper. margin | -237.58% |
Gross margin | 0% |
EBIT margin | -237.58% |
EBITDA margin | -2373.23% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeReNeuron Group stock price history
ReNeuron Group stock forecast
ReNeuron Group financial statements
| Dec 2022 | 46K | -1.11M | -2426.09% |
|---|---|---|---|
| Mar 2023 | 92K | -2.23M | -2426.09% |
| Jun 2023 | 78.5K | -1.42M | -1809.55% |
| Sep 2023 | 157K | -2.84M | -1809.55% |
| Sep 2022 | 13827000 | 6.74M | 48.78% |
|---|---|---|---|
| Dec 2022 | 9645000 | 4.32M | 44.79% |
| Jun 2023 | 6423000 | 4.00M | 62.31% |
| Sep 2023 | 6423000 | 4.00M | 62.31% |
| Dec 2022 | -1.58M | 2.01M | -2.04M |
|---|---|---|---|
| Mar 2023 | -3.06M | 3.93M | -4.08M |
| Jun 2023 | -1.05M | 555K | -38K |
| Sep 2023 | -1.99M | 1M | -76K |
ReNeuron Group alternative data
| Aug 2023 | 26 |
|---|---|
| Sep 2023 | 26 |
| Oct 2023 | 26 |
| Nov 2023 | 26 |
| Dec 2023 | 26 |
| Jan 2024 | 26 |
| Feb 2024 | 26 |
| Mar 2024 | 26 |
| Apr 2024 | 26 |
| May 2024 | 26 |
| Jun 2024 | 26 |
| Jul 2024 | 26 |
ReNeuron Group other data
| Insider | Compensation |
|---|---|
Mr. Olav Hellebo BBA, MBA (1965) Chief Executive Officer & Director | $488,000 |
-
What's the price of ReNeuron Group stock today?
One share of ReNeuron Group stock can currently be purchased for approximately $82.
-
When is ReNeuron Group's next earnings date?
Unfortunately, ReNeuron Group's (RENE.L) next earnings date is currently unknown.
-
Does ReNeuron Group pay dividends?
No, ReNeuron Group does not pay dividends.
-
How much money does ReNeuron Group make?
ReNeuron Group has a market capitalization of 1.92M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 56.81% to 403K US dollars.
-
What is ReNeuron Group's stock symbol?
ReNeuron Group plc is traded on the LSE under the ticker symbol "RENE.L".
-
What is ReNeuron Group's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ReNeuron Group?
Shares of ReNeuron Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ReNeuron Group's key executives?
ReNeuron Group's management team includes the following people:
- Mr. Olav Hellebo BBA, MBA Chief Executive Officer & Director(age: 60, pay: $488,000)
-
How many employees does ReNeuron Group have?
As Jul 2024, ReNeuron Group employs 26 workers.
-
When ReNeuron Group went public?
ReNeuron Group plc is publicly traded company for more then 20 years since IPO on 12 Aug 2005.
-
What is ReNeuron Group's official website?
The official website for ReNeuron Group is reneuron.com.
-
How can i contact ReNeuron Group?
ReNeuron Group can be reached via phone at +44 20 3819 8400.
ReNeuron Group company profile:
ReNeuron Group plc
reneuron.comLSE
26
Biotechnology
Healthcare
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Pencoed, CF35 5HY
:
ISIN: GB00BF5G6K95
CUSIP: G7489A121
